{"id":"W2590868182","doi":"10.1200/jco.2015.33.7_suppl.430","title":"Third-line therapy in metastatic renal cell carcinoma: Results from the International mRCC Database Consortium.","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"ca_institutions":"Ottawa Regional Cancer Foundation; Queen Elizabeth II Health Sciences Centre; Princess Margaret Cancer Centre; BC Cancer Agency; University Health Network; University of Toronto; Sunnybrook Health Science Centre; University of Calgary","funders":"","keywords":"Medicine; Sunitinib; Pazopanib; Sorafenib; Internal medicine; Hazard ratio; Targeted therapy; Oncology; Renal cell carcinoma; Temsirolimus; Salvage therapy; Everolimus; Proportional hazards model; Surgery; Cancer; Chemotherapy; Confidence interval; Hepatocellular carcinoma","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.006259655,0.000397863,0.001095358,0.003809545,0.0003996872,0.002162131,0.00108013,0.0006681236,0.002316541],"category_scores_gemma":[0.01638048,0.0002261006,0.00142145,0.01029037,0.0002659005,0.00104854,0.001533949,0.0005387482,0.0007097604],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.002323068,"about_ca_system_score_gemma":0.002513004,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.04052632,"about_ca_topic_score_gemma":0.0349649,"domain_scores_codex":[0.9935052,0.001962093,0.001268464,0.001002439,0.001889895,0.0003718562],"domain_scores_gemma":[0.9788759,0.00561119,0.009372817,0.001334983,0.003085767,0.001719278],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.001723613,0.00008945484,0.9722706,0.0009357026,0.001268194,0.0001378263,0.0001966154,0.0004322358,0.0001017759,0.0000890372,0.01225179,0.01050318],"study_design_scores_gemma":[0.0002979367,0.0001574471,0.9911872,0.000283893,0.000724515,0.0003809419,0.0003525669,0.001030726,0.0001554475,0.00003686724,0.005363523,0.00002884738],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.7204032,0.01282247,0.000312452,0.001038332,0.00004291029,0.0002624811,0.2622584,0.00008951498,0.002770385],"genre_scores_gemma":[0.7804346,0.003071985,0.0005761366,0.0004474204,0.00005741593,0.0002987038,0.2145821,0.00004056493,0.0004912635],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.04052632,"threshold_uncertainty_score":0.08058089,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.2966878869028001,"score_gpt":0.4566390676937862,"score_spread":0.1599511807909861,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}